27 research outputs found

    OAE: The Ontology of Adverse Events

    Get PDF
    A medical intervention is a medical procedure or application intended to relieve or prevent illness or injury. Examples of medical interventions include vaccination and drug administration. After a medical intervention, adverse events (AEs) may occur which lie outside the intended consequences of the intervention. The representation and analysis of AEs are critical to the improvement of public health. Description: The Ontology of Adverse Events (OAE), previously named Adverse Event Ontology (AEO), is a community-driven ontology developed to standardize and integrate data relating to AEs arising subsequent to medical interventions, as well as to support computer-assisted reasoning. OAE has over 3,000 terms with unique identifiers, including terms imported from existing ontologies and more than 1,800 OAE-specific terms. In OAE, the term โ€˜adverse eventโ€™ denotes a pathological bodily process in a patient that occurs after a medical intervention. Causal adverse events are defined by OAE as those events that are causal consequences of a medical intervention. OAE represents various adverse events based on patient anatomic regions and clinical outcomes, including symptoms, signs, and abnormal processes. OAE has been used in the analysis of several different sorts of vaccine and drug adverse event data

    OAE: The Ontology of Adverse Events

    Get PDF
    A medical intervention is a medical procedure or application intended to relieve or prevent illness or injury. Examples of medical interventions include vaccination and drug administration. After a medical intervention, adverse events (AEs) may occur which lie outside the intended consequences of the intervention. The representation and analysis of AEs are critical to the improvement of public health. Description: The Ontology of Adverse Events (OAE), previously named Adverse Event Ontology (AEO), is a community-driven ontology developed to standardize and integrate data relating to AEs arising subsequent to medical interventions, as well as to support computer-assisted reasoning. OAE has over 3,000 terms with unique identifiers, including terms imported from existing ontologies and more than 1,800 OAE-specific terms. In OAE, the term โ€˜adverse eventโ€™ denotes a pathological bodily process in a patient that occurs after a medical intervention. Causal adverse events are defined by OAE as those events that are causal consequences of a medical intervention. OAE represents various adverse events based on patient anatomic regions and clinical outcomes, including symptoms, signs, and abnormal processes. OAE has been used in the analysis of several different sorts of vaccine and drug adverse event data

    OAE: The Ontology of Adverse Events

    Full text link

    Ontology-Based Combinatorial Comparative Analysis of Adverse Events Associated with Killed and Live Influenza Vaccines

    Get PDF
    Vaccine adverse events (VAEs) are adverse bodily changes occurring after vaccination. Understanding the adverse event (AE) profiles is a crucial step to identify serious AEs. Two different types of seasonal influenza vaccines have been used on the market: trivalent (killed) inactivated influenza vaccine (TIV) and trivalent live attenuated influenza vaccine (LAIV). Different adverse event profiles induced by these two groups of seasonal influenza vaccines were studied based on the data drawn from the CDC Vaccine Adverse Event Report System (VAERS). Extracted from VAERS were 37,621 AE reports for four TIVs (Afluria, Fluarix, Fluvirin, and Fluzone) and 3,707 AE reports for the only LAIV (FluMist). The AE report data were analyzed by a novel combinatorial, ontology-based detection of AE method (CODAE). CODAE detects AEs using Proportional Reporting Ratio (PRR), Chi-square significance test, and base level filtration, and groups identified AEs by ontology-based hierarchical classification. In total, 48 TIV-enriched and 68 LAIV-enriched AEs were identified (PRR.2, Chi-square score .4, and the number of cases .0.2% of total reports). These AE terms were classified using the Ontology of Adverse Events (OAE), MedDRA, and SNOMED-CT. The OAE method provided better classification results than the two other methods. Thirteen out of 48 TIV-enriched AEs were related to neurological and muscular processing such as paralysis, movement disorders, and muscular weakness. In contrast, 15 out of 68 LAIV-enriched AEs were associated with inflammatory response and respiratory system disorders. There were evidences of two severe adverse events (Guillain-Barre Syndrome and paralysis) present in TIV. Although these severe adverse events were at low incidence rate, they were found to be more significantly enriched in TIVvaccinated patients than LAIV-vaccinated patients. Therefore, our novel combinatorial bioinformatics analysis discovered that LAIV had lower chance of inducing these two severe adverse events than TIV. In addition, our meta-analysis found that all previously reported positive correlation between GBS and influenza vaccine immunization were based on trivalent influenza vaccines instead of monovalent influenza vaccines.This work was supported by the National Institutes of Health (NIH) grant U54 DA021519 for the National Center for Integrative Biomedical Informatics and NIH National Institute of Allergy and Infectious Diseases (NIAID) grant R01AI081062. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/99110/1/journal.pone.0049941.pd

    A 2012 Workshop: Vaccine and Drug Ontology in the Study of Mechanism and Effect (VDOSME 2012)

    Full text link

    Computational Advances in Drug Safety: Systematic and Mapping Review of Knowledge Engineering Based Approaches

    Get PDF
    Drug Safety (DS) is a domain with significant public health and social impact. Knowledge Engineering (KE) is the Computer Science discipline elaborating on methods and tools for developing โ€œknowledge-intensiveโ€ systems, depending on a conceptual โ€œknowledgeโ€ schema and some kind of โ€œreasoningโ€ process. The present systematic and mapping review aims to investigate KE-based approaches employed for DS and highlight the introduced added value as well as trends and possible gaps in the domain. Journal articles published between 2006 and 2017 were retrieved from PubMed/MEDLINE and Web of Scienceยฎ (873 in total) and filtered based on a comprehensive set of inclusion/exclusion criteria. The 80 finally selected articles were reviewed on full-text, while the mapping process relied on a set of concrete criteria (concerning specific KE and DS core activities, special DS topics, employed data sources, reference ontologies/terminologies, and computational methods, etc.). The analysis results are publicly available as online interactive analytics graphs. The review clearly depicted increased use of KE approaches for DS. The collected data illustrate the use of KE for various DS aspects, such as Adverse Drug Event (ADE) information collection, detection, and assessment. Moreover, the quantified analysis of using KE for the respective DS core activities highlighted room for intensifying research on KE for ADE monitoring, prevention and reporting. Finally, the assessed use of the various data sources for DS special topics demonstrated extensive use of dominant data sources for DS surveillance, i.e., Spontaneous Reporting Systems, but also increasing interest in the use of emerging data sources, e.g., observational healthcare databases, biochemical/genetic databases, and social media. Various exemplar applications were identified with promising results, e.g., improvement in Adverse Drug Reaction (ADR) prediction, detection of drug interactions, and novel ADE profiles related with specific mechanisms of action, etc. Nevertheless, since the reviewed studies mostly concerned proof-of-concept implementations, more intense research is required to increase the maturity level that is necessary for KE approaches to reach routine DS practice. In conclusion, we argue that efficiently addressing DS data analytics and management challenges requires the introduction of high-throughput KE-based methods for effective knowledge discovery and management, resulting ultimately, in the establishment of a continuous learning DS system

    ์•ฝ๋ฌผ ๊ฐ์‹œ๋ฅผ ์œ„ํ•œ ๋น„์ •ํ˜• ํ…์ŠคํŠธ ๋‚ด ์ž„์ƒ ์ •๋ณด ์ถ”์ถœ ์—ฐ๊ตฌ

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ(๋ฐ•์‚ฌ) -- ์„œ์šธ๋Œ€ํ•™๊ต๋Œ€ํ•™์› : ์œตํ•ฉ๊ณผํ•™๊ธฐ์ˆ ๋Œ€ํ•™์› ์‘์šฉ๋ฐ”์ด์˜ค๊ณตํ•™๊ณผ, 2023. 2. ์ดํ˜•๊ธฐ.Pharmacovigilance is a scientific activity to detect, evaluate and understand the occurrence of adverse drug events or other problems related to drug safety. However, concerns have been raised over the quality of drug safety information for pharmacovigilance, and there is also a need to secure a new data source to acquire drug safety information. On the other hand, the rise of pre-trained language models based on a transformer architecture has accelerated the application of natural language processing (NLP) techniques in diverse domains. In this context, I tried to define two problems in pharmacovigilance as an NLP task and provide baseline models for the defined tasks: 1) extracting comprehensive drug safety information from adverse drug events narratives reported through a spontaneous reporting system (SRS) and 2) extracting drug-food interaction information from abstracts of biomedical articles. I developed annotation guidelines and performed manual annotation, demonstrating that strong NLP models can be trained to extracted clinical information from unstructrued free-texts by fine-tuning transformer-based language models on a high-quality annotated corpus. Finally, I discuss issues to consider when when developing annotation guidelines for extracting clinical information related to pharmacovigilance. The annotated corpora and the NLP models in this dissertation can streamline pharmacovigilance activities by enhancing the data quality of reported drug safety information and expanding the data sources.์•ฝ๋ฌผ ๊ฐ์‹œ๋Š” ์•ฝ๋ฌผ ๋ถ€์ž‘์šฉ ๋˜๋Š” ์•ฝ๋ฌผ ์•ˆ์ „์„ฑ๊ณผ ๊ด€๋ จ๋œ ๋ฌธ์ œ์˜ ๋ฐœ์ƒ์„ ๊ฐ์ง€, ํ‰๊ฐ€ ๋ฐ ์ดํ•ดํ•˜๊ธฐ ์œ„ํ•œ ๊ณผํ•™์  ํ™œ๋™์ด๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ์•ฝ๋ฌผ ๊ฐ์‹œ์— ์‚ฌ์šฉ๋˜๋Š” ์˜์•ฝํ’ˆ ์•ˆ์ „์„ฑ ์ •๋ณด์˜ ๋ณด๊ณ  ํ’ˆ์งˆ์— ๋Œ€ํ•œ ์šฐ๋ ค๊ฐ€ ๊พธ์ค€ํžˆ ์ œ๊ธฐ๋˜์—ˆ์œผ๋ฉฐ, ํ•ด๋‹น ๋ณด๊ณ  ํ’ˆ์งˆ์„ ๋†’์ด๊ธฐ ์œ„ํ•ด์„œ๋Š” ์•ˆ์ „์„ฑ ์ •๋ณด๋ฅผ ํ™•๋ณดํ•  ์ƒˆ๋กœ์šด ์ž๋ฃŒ์›์ด ํ•„์š”ํ•˜๋‹ค. ํ•œํŽธ ํŠธ๋žœ์Šคํฌ๋จธ ์•„ํ‚คํ…์ฒ˜๋ฅผ ๊ธฐ๋ฐ˜์œผ๋กœ ์‚ฌ์ „ํ›ˆ๋ จ ์–ธ์–ด๋ชจ๋ธ์ด ๋“ฑ์žฅํ•˜๋ฉด์„œ ๋‹ค์–‘ํ•œ ๋„๋ฉ”์ธ์—์„œ ์ž์—ฐ์–ด์ฒ˜๋ฆฌ ๊ธฐ์ˆ  ์ ์šฉ์ด ๊ฐ€์†ํ™”๋˜์—ˆ๋‹ค. ์ด๋Ÿฌํ•œ ๋งฅ๋ฝ์—์„œ ๋ณธ ํ•™์œ„ ๋…ผ๋ฌธ์—์„œ๋Š” ์•ฝ๋ฌผ ๊ฐ์‹œ๋ฅผ ์œ„ํ•œ ๋‹ค์Œ 2๊ฐ€์ง€ ์ •๋ณด ์ถ”์ถœ ๋ฌธ์ œ๋ฅผ ์ž์—ฐ์–ด์ฒ˜๋ฆฌ ๋ฌธ์ œ ํ˜•ํƒœ๋กœ ์ •์˜ํ•˜๊ณ  ๊ด€๋ จ ๊ธฐ์ค€ ๋ชจ๋ธ์„ ๊ฐœ๋ฐœํ•˜์˜€๋‹ค: 1) ์ˆ˜๋™์  ์•ฝ๋ฌผ ๊ฐ์‹œ ์ฒด๊ณ„์— ๋ณด๊ณ ๋œ ์ด์ƒ์‚ฌ๋ก€ ์„œ์ˆ ์ž๋ฃŒ์—์„œ ํฌ๊ด„์ ์ธ ์•ฝ๋ฌผ ์•ˆ์ „์„ฑ ์ •๋ณด๋ฅผ ์ถ”์ถœํ•œ๋‹ค. 2) ์˜๋ฌธ ์˜์•ฝํ•™ ๋…ผ๋ฌธ ์ดˆ๋ก์—์„œ ์•ฝ๋ฌผ-์‹ํ’ˆ ์ƒํ˜ธ์ž‘์šฉ ์ •๋ณด๋ฅผ ์ถ”์ถœํ•œ๋‹ค. ์ด๋ฅผ ์œ„ํ•ด ์•ˆ์ „์„ฑ ์ •๋ณด ์ถ”์ถœ์„ ์œ„ํ•œ ์–ด๋…ธํ…Œ์ด์…˜ ๊ฐ€์ด๋“œ๋ผ์ธ์„ ๊ฐœ๋ฐœํ•˜๊ณ  ์ˆ˜์ž‘์—…์œผ๋กœ ์–ด๋…ธํ…Œ์ด์…˜์„ ์ˆ˜ํ–‰ํ•˜์˜€๋‹ค. ๊ฒฐ๊ณผ์ ์œผ๋กœ ๊ณ ํ’ˆ์งˆ์˜ ์ž์—ฐ์–ด ํ•™์Šต๋ฐ์ดํ„ฐ๋ฅผ ๊ธฐ๋ฐ˜์œผ๋กœ ์‚ฌ์ „ํ•™์Šต ์–ธ์–ด๋ชจ๋ธ์„ ๋ฏธ์„ธ ์กฐ์ •ํ•จ์œผ๋กœ์จ ๋น„์ •ํ˜• ํ…์ŠคํŠธ์—์„œ ์ž„์ƒ ์ •๋ณด๋ฅผ ์ถ”์ถœํ•˜๋Š” ๊ฐ•๋ ฅํ•œ ์ž์—ฐ์–ด์ฒ˜๋ฆฌ ๋ชจ๋ธ ๊ฐœ๋ฐœ์ด ๊ฐ€๋Šฅํ•จ์„ ํ™•์ธํ•˜์˜€๋‹ค. ๋งˆ์ง€๋ง‰์œผ๋กœ ๋ณธ ํ•™์œ„ ๋…ผ๋ฌธ์—์„œ๋Š” ์•ฝ๋ฌผ๊ฐ์‹œ์™€ ๊ด€๋ จ๋œ์ž„์ƒ ์ •๋ณด ์ถ”์ถœ์„ ์œ„ํ•œ ์–ด๋…ธํ…Œ์ด์…˜ ๊ฐ€์ด๋“œ๋ผ์ธ์„ ๊ฐœ๋ฐœํ•  ๋•Œ ๊ณ ๋ คํ•ด์•ผ ํ•  ์ฃผ์˜ ์‚ฌํ•ญ์— ๋Œ€ํ•ด ๋…ผ์˜ํ•˜์˜€๋‹ค. ๋ณธ ํ•™์œ„ ๋…ผ๋ฌธ์—์„œ ์†Œ๊ฐœํ•œ ์ž์—ฐ์–ด ํ•™์Šต๋ฐ์ดํ„ฐ์™€ ์ž์—ฐ์–ด์ฒ˜๋ฆฌ ๋ชจ๋ธ์€ ์•ฝ๋ฌผ ์•ˆ์ „์„ฑ ์ •๋ณด์˜ ๋ณด๊ณ  ํ’ˆ์งˆ์„ ํ–ฅ์ƒ์‹œํ‚ค๊ณ  ์ž๋ฃŒ์›์„ ํ™•์žฅํ•˜์—ฌ ์•ฝ๋ฌผ ๊ฐ์‹œ ํ™œ๋™์„ ๋ณด์กฐํ•  ๊ฒƒ์œผ๋กœ ๊ธฐ๋Œ€๋œ๋‹ค.Chapter 1 1 1.1 Contributions of this dissertation 2 1.2 Overview of this dissertation 2 1.3 Other works 3 Chapter 2 4 2.1 Pharmacovigilance 4 2.2 Biomedical NLP for pharmacovigilance 6 2.2.1 Pre-trained language models 6 2.2.2 Corpora to extract clinical information for pharmacovigilance 9 Chapter 3 11 3.1 Motivation 12 3.2 Proposed Methods 14 3.2.1 Data source and text corpus 15 3.2.2 Annotation of ADE narratives 16 3.2.3 Quality control of annotation 17 3.2.4 Pretraining KAERS-BERT 18 3.2.6 Named entity recognition 20 3.2.7 Entity label classification and sentence extraction 21 3.2.8 Relation extraction 21 3.2.9 Model evaluation 22 3.2.10 Ablation experiment 23 3.3 Results 24 3.3.1 Annotated ICSRs 24 3.3.2 Corpus statistics 26 3.3.3 Performance of NLP models to extract drug safety information 28 3.3.4 Ablation experiment 31 3.4 Discussion 33 3.5 Conclusion 38 Chapter 4 39 4.1 Motivation 39 4.2 Proposed Methods 43 4.2.1 Data source 44 4.2.2 Annotation 45 4.2.3 Quality control of annotation 49 4.2.4 Baseline model development 49 4.3 Results 50 4.3.1 Corpus statistics 50 4.3.2 Annotation Quality 54 4.3.3 Performance of baseline models 55 4.3.4 Qualitative error analysis 56 4.4 Discussion 59 4.5 Conclusion 63 Chapter 5 64 5.1 Issues around defining a word entity 64 5.2 Issues around defining a relation between word entities 66 5.3 Issues around defining entity labels 68 5.4 Issues around selecting and preprocessing annotated documents 68 Chapter 6 71 6.1 Dissertation summary 71 6.2 Limitation and future works 72 6.2.1 Development of end-to-end information extraction models from free-texts to database based on existing structured information 72 6.2.2 Application of in-context learning framework in clinical information extraction 74 Chapter 7 76 7.1 Annotation Guideline for "Extraction of Comprehensive Drug Safety Information from Adverse Event Narratives Reported through Spontaneous Reporting System" 76 7.2 Annotation Guideline for "Extraction of Drug-Food Interactions from the Abtracts of Biomedical Articles" 100๋ฐ•
    corecore